Get Premium to unlock powerful stock data
BUE:AMGN (USA)  
Amgen Inc logo

Amgen Inc

ARS 360.50 (0%) Jul 1
On watch
P/E:
24.17
P/B:
143.18
Market Cap:
ARS 16.43T ($ 130.39B)
Enterprise V:
ARS 20.22T ($ 160.52B)
Volume:
-
Avg Vol (2M):
-
Also Trade In:
Volume:
-
Market Cap ARS:
16.43T
Market Cap $:
130.39B
PE Ratio:
24.17
Avg Vol (2-Month):
-
Enterprise Value ARS:
20.22T
Enterprise Value $:
160.52B
PB Ratio:
143.18
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download Tutorials

Business Description

Description
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Name Current Vs Industry Vs History
Cash-To-Debt 0.18
Equity-to-Asset 0.02
Debt-to-Equity 40.23
Debt-to-EBITDA 3.31
Interest Coverage 7.89
Piotroski F-Score 5/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 1.64
Distress
Grey
Safe
Beneish M-Score -2.51
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.44
Quick Ratio 1.09
Cash Ratio 0.51
Days Inventory 232.49
Days Sales Outstanding 65.57
Days Payable 73.98

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Dividend Growth Rate 10.1
3-Year Average Share Buyback Ratio 3.9

Financials (Next Earnings Date:2022-08-03 Est.)

BUE:AMGN's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil ARS) 2,635,085.077
EPS (TTM) (ARS) 5137.334
Beta 0
Volatility % 8.91
14-Day RSI 0
14-Day ATR (ARS) 0
20-Day SMA (ARS) 360.5
12-1 Month Momentum % 0
52-Week Range (ARS) 360.5 - 360.5
Shares Outstanding (Mil) 106.84

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Amgen Inc Filings

Document Form Filing Date
No Filing Data